In a filing dated September 12, 2025, to BSE and NSE, the company stated, “Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that AstraZeneca Pharma India Limited (‘the Company’) has received a Show Cause Notice from National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India on September 11, 2025.” According to the annexure submitted along with the disclosure, NPPA, in its notice, has alleged that the company “has overcharged for batches of ‘Symbicort Turbuhaler’ Inhalation Powder, 60 Doses each, by marketing or manufacturing them at prices above the notified ceiling price subsequent to the relevant price notifications issued for the period from April 2016 to July 2025.” The company has been given 30 days to submit its response to these allegations.